Search

Displaying results 3461 - 3470 of 8010 in total
  1. Drug

    Sonrotoclax

    go.drugbank.com/drugs/DB18753
    ApprovedInvestigational

    It is the first BCL-2 inhibitor approved for MCL and the second oncology-approved BCL-2 inhibitor overall, following venetoclax. … [A275521,A275522] On May 13, 2026, the FDA granted accelerated approval to sonrotoclax for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two prior

  2. Drug

    APT20TTMG

    go.drugbank.com/drugs/DB32869
    Experimental

    APT20TTMG is a synthetic DNA that modulates U1 small nuclear ribonucleoprotein misassembly.

  3. Drug

    Troglitazone

    go.drugbank.com/drugs/DB00197
    ApprovedWithdrawn

    It was superseded by [pioglitazone] and [rosiglitazone].

  4. Drug

    Pancuronium

    go.drugbank.com/drugs/DB01337
    Approved

    As a neuromuscular blocking agent it is more potent than curare but has less effect on the circulatory system and on histamine release.

  5. Drug

    Icodextrin

    go.drugbank.com/drugs/DB00702
    ApprovedInvestigational

    It is used primarily for ambulatory peritoneal dialysis (CAPD) of diabetic patients and automated peritoneal dialysis (APD) for patients with end-stage renal disease.

    Categories: Compounds used in a research, industrial, or household setting
  6. Drug

    Flunisolide

    go.drugbank.com/drugs/DB00180
    Approved

    It is often prescribed as treatment for allergic rhinitis and its principle mechanism of action involves activation of glucocorticoid receptors.

    Categories: Corticosteroids for Systemic Use, Drugs for Obstructive Airway Diseases
  7. Drug

    TG100-115

    go.drugbank.com/drugs/DB05552
    Investigational

    An NSAID that inhibits PI-3K gamma and delta.

  8. Drug

    Prezatide

    go.drugbank.com/drugs/DB11296
    Approved

    Prezatide is used in cosmetic products for the skin and hair.

  9. Drug

    Ad5-nCoV

    go.drugbank.com/drugs/DB15655
    Investigational

    Ad5-nCoV is a recombinant adenovirus type-5 vector (Ad5) vaccine currently being investigated for prophylaxis against SARS-CoV-2. … The study will evaluate antibody response in healthy patients between the ages of 18 and 60 who will receive one of three study doses, with follow-up taking place at weeks 2 and 4 and months 3 and 6 post-vaccination

    Categories: Experimental Unapproved Treatments for COVID-19
  10. Drug

    Chlorphenoxamine

    go.drugbank.com/drugs/DB09007
    ApprovedWithdrawn

    It is an antihistamine and anticholinergic used to treat itching as well as for its antiparkinsonian effect.

    Categories: Antihistamines for Topical Use, Antihistamines for Systemic Use